Insights From Expert Practice℠ in Pancreatic Cancer
Webcast
Webcast

Insights From Expert Practice℠ in Pancreatic Cancer

Not a member of My prIME? Join now for instant access.

Gain insight on molecular biology, imaging, and current standard of care in resectable, unresectable, and metastatic pancreatic cancer. This activity features expert faculty video presentations with downloadable slides from our Expert Practice℠ in Pancreatic Cancer meeting.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Nov 3, 2017

Expiration Date

Nov 3, 2018

Setting the stage: Key milestones and challenges in the management of pancreatic cancer
Eric Van Cutsem, MD, PhD

Hot topic debate: Should every patient with resectable pancreatic cancer receive upfront chemotherapy?
Yes: Christiane Bruns, MD, PhD
No: Gabriela Chiorean, MD

Keynote Lecture 1—Advances in molecular biology of pancreatic cancer: Understanding genetic complexity and molecular heterogeneity
Volker Ellenrieder, MD, PhD

Imaging of pancreatic cancer: Current state of the art and future trends
Maria Antonietta Bali, MD, PhD

Case #1—Resectable pancreatic ductal carcinoma
Part I: Advances in surgery
Christiane Bruns, MD, PhD

Case #1—Resectable pancreatic ductal carcinoma
Part II: Current and emerging adjuvant therapies
Part III: Managing borderline resectable pancreatic cancer and follow-up strategies
Teresa Macarulla, MD, PhD

Case #2—Locally advanced unresectable pancreatic cancer: Evaluating treatment options
Stefano Cascinu, MD, PhD

Selecting the primary endpoint for neoadjuvant and adjuvant clinical trials
Eric Van Cutsem, MD, PhD, and Faculty Panel

Keynote Lecture 2—Targeting the tumor microenvironment in pancreatic cancer
Gabriela Chiorean, MD

Case #3—Metastatic pancreatic ductal adenocarcinoma: Selecting an optimal first-line approach
Philip Agop Philip, MD, PhD, FRCP

Case #4—Progressive pancreatic cancer: Optimal sequencing of systemic therapy?
Gerald Prager, MD

Pancreatic cancer management in the coming year: What can we expect?
Philip Agop Philip, MD, PhD, FRCP

prIME Points™
Eric Van Cutsem, MD, PhD

  • Maria Antonietta Bali, MD, PhDRoyal Marsden Hospital, London, United Kingdom
    Erasmus Hospital, Free University of Brussels
    Brussels, Belgium
  • Christiane Bruns, MD, PhDUniversity of Cologne
    Cologne, Germany
  • Stefano Cascinu, MD, PhDUniversity of Modena and Reggio Emilia
    Modena, Italy
  • Gabriela Chiorean, MDUniversity of Washington
    Fred Hutchinson Cancer Research Center
    Seattle, Washington, United States
  • Volker Ellenrieder, MD, PhDUniversity Hospital Gӧttingen
    Gӧttingen, Germany
  • Teresa Macarulla, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Philip Agop Philip, MD, PhD, FRCPWayne State University and Karmanos Cancer Institute
    Detroit, Michigan, United States
  • Gerald Prager, MDMedical University of Vienna
    Vienna, Austria
  • Eric Van Cutsem, MD, PhDUniversity Hospitals Leuven
    Leuven, Belgium

This educational activity is designed for European surgical, radiation, and medical oncologists, gastroenterologists, and other healthcare providers involved in the management of patients with pancreatic cancer.

After successful completion of this educational activity, participants should be able to:

  • Describe the genomic complexity and molecular heterogeneity of pancreatic cancer
  • Explain advances in imaging modalities of pancreatic cancer and recognize imaging criteria defining resectability
  • Identify multimodality treatment strategies for localized resectable, borderline, and unresectable pancreatic cancer
  • Select the most appropriate therapeutic approach for metastatic pancreatic ductal adenocarcinoma based on patient and disease characteristics, both in the first-line setting and beyond
  • Assess supportive care measures to ameliorate disease symptoms and treatment-related adverse events throughout the course of pancreatic cancer management
  • Describe emerging treatment strategies in pancreatic cancer, including the role of immunotherapy

This educational activity is supported by grants from Celgene and Shire.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.